High density of M1 TAMs (CD86+ TAMs) predicted better survival in HCC patients, while high density of M2 TAMs (CD204+ and CD206+ TAMs) or CD169+ TAMs predicted worse survival. This evidence concerns the gene CD86 and hepatocellular carcinoma.